Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of HSC in Female Pattern Hair Loss
NCT03662854Phase 1Unknown
- Sponsor
- Histogen Inc.
- Start
- Jul 2018
- Primary completion
- Jan 2019
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HST-001 in Female Pattern Hair Loss (FPHL) (2 arms), sponsored by Histogen Inc. Primary endpoint: Number of Adverse Events due to HSC at 22 weeks. Status: unknown.
02
Drugs
HST-001
03
Conditions
Female Pattern Hair Loss (FPHL)
Beyond the preview
Go deeper on NCT03662854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03662854.